The gene expression examination reveals the tips on asbestos -interstitial miracle

The expression of genes leading to DNA changes caused by asbestos exposure can explain the development of malignant pleural interstitis (MPM), rare and aggressive cancer. Analyzing public RNA-SEQ data through a comprehensive bioinformatic pipeline, scientists cooperating with the SBARRO (SHRO) health research organization have developed a in-depth picture of molecular mechanisms involved in carcinogens induced by asbestos. The discoveries emphasize both known and new genes and paths, providing valuable insight into biological processes disturbed in exposed patients. This work contributes to constant efforts to define reliable diagnostic and prognostic biomarkers and are the basis for future research and potential clinical applications in personalized approaches to MPM management.

The article, entitled “From asbestos exposure to carcinogenicity: transcriptomous signatures in malicious pleural miracle”, describes a new study examining the expression of differential genes in the malicious mesoteloma between them (MPM) associated with documented asbestos exposure, in order to identify specific transabilities biomarkers, which They can support preliminary progress.

Published in a document, which was a joint effort between the teams led by Professor Antonio Giordano, Dr. MD, founder and director of SHRO and professor at the University of Temple, and Professor Elisa Frullanti, Dr. Lab Genomics and Cancer Genomics & Systems Biology Lab and Professor Genetics. The study was conducted at the Med Biotech Hub and Compense Center at the University of Siena, in cooperation with SHRO and SBARRO Institute for Molecular Medicine and Cancer Research at Temple University. Financing was delivered by the Italian National Institute of Insurance against accidents at work (inail) via the BRIC-Vail 2022 program. The co-authors are Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angel Rina, Francesca Mari and Maria Palmieri.

Using publicly available RNA sequencing sequences, the research team used a comprehensive bioinform pipeline to conduct a differential expression of genes and analyzes of functional enrichment. The results identified a separate set of genes of various expression (DEG) in patients with MPM with documented asbestos exposure. Many of these genes participate in key biological processes, such as ion homeostasis, reaction to oxidative stress and halmar components of cellular components induced by asbestos, which can play a role in initiating and conducting tumor.

It’s not just about cataloging genes. It is about constructing a molecular map of road development of cancer caused by asbestos. With further validation, this can translate into real clinical applications. “

Professor Elisa Frullanti, director of the Biology Laboratory and Cancer Genomics & Systems and Professor of Genetics at the University of Siena

Discoveries shed new light on MPM molecular mechanisms and form the basis for future research on predictive and prognostic biomarkers. Indicating specific transcriptomous changes, the study contributes to efforts in precision medicine and supports the development of improved diagnostic tools and potential therapeutic goals for this deadly disease.

“This type of precision medicine means that we are a step closer to patient identification more likely that the development of malignant pleural interstitus,” says Giordano, “and we are closer to the development of potential treatment methods.”

Because the global incidence of interstitations still increases partly to the long period of exposure to asbestos and continuous environmental risk-this study is a key step towards more personalized and effective patient management strategies.